ReACT Therapeutics develops ValOMé, a molecule that inhibits the BCRP protein responsible for multidrug resistance in cancer treatment. By enhancing the efficacy of various anticancer therapies, ValOMé aims to improve patient outcomes and quality of care.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers develop resistance to anticancer treatments due to the overexpression of the BCRP (Breast Cancer Resistance Protein), which pumps drugs out of cancer cells, reducing their efficacy. This multidrug resistance leads to treatment failure and poorer outcomes for patients undergoing chemotherapy, targeted therapy, hormone therapy, or immunotherapy.
Solution
ReACT Therapeutics is developing ValOMé, a molecule designed to inhibit the BCRP protein and restore the effectiveness of anticancer drugs. By blocking the efflux of drugs from cancer cells, ValOMé increases the intracellular concentration of the therapeutic agent, thereby enhancing its cytotoxic effect. ValOMé is designed to be used in combination with a range of anticancer therapies, including chemotherapies, targeted therapies, hormone therapies, and immunotherapies, to overcome drug resistance and improve treatment outcomes. The goal is to provide a selective and non-toxic solution that can be integrated into existing cancer treatment regimens to improve patient care and quality of life.
Target Audience
The primary target audience includes oncologists and cancer patients undergoing treatment with chemotherapies, targeted therapies, hormone therapies, or immunotherapies who have developed or are at risk of developing BCRP-mediated drug resistance.
Features
- ValOMé is a small molecule inhibitor specifically targeting the BCRP protein.
- Designed to be used in combination with existing anticancer therapies.
- Aims to restore drug sensitivity in multidrug-resistant cancers.
- May be combined with chemotherapies, targeted therapies, hormone therapies, and immunotherapies.